Home > Keywords >
Catalog | name | Description | price |
---|---|---|---|
R-R-4849 | TPB-TP-COF Cas.1262433-88-4 | TPB-TP-COF/TPB-TP-covalent organic framework/Cas.1262433-88-4 stands for Tetraphenylbenzidine-Triptycene-Covalent Organic Framework. This material is a type of covalent organic framework (COF) that is designed with specific organic building blocks to create a structured and porous network held together by strong covalent bonds.The combination of these building blocks in TPB-TP-COF results in a well-defined and potentially tunable material with tailored electronic and structural properties. COFs like TPB-TP-COF are of interest in various applications such as gas storage, catalysis, and sensing due to their ordered structure, porosity, and potential for selective adsorption of molecules. | price> |
R-C-3180 | AZD9567 CAS:1893415-00-3 | AZD9567 (compound 15) is a potent, oral active, non-steroidal and selective glucocorticoid receptor modulator (SGRM), with an IC50 of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall(SCW)reactivation model of joint inflammation. | price> |
R-R-4850 | DAAQ-TFP COF Cas No.1477485-46-3 | DAAQ-TFP COF/2,6-Diaminoanthraquinone-1,3,5-Triformylphloroglucinol covalent organic framework/Cas No.1477485-46-3 from ruixi. The covalent organic framework (COF) formed by 2,6-diaminoanthraquinone (DAAQ) and 1,3,5-triformylphloroglucinol is a unique structured material with specific properties derived from the combination of these two key building blocks. 2,6-Diaminoanthraquinone is a molecule containing two amino groups attached to an anthraquinone core. 1,3,5-Triformylphloroglucinol is a molecule with three aldehyde functional groups arranged on a phloroglucinol backbone. When these two components are combined through covalent bonds to create a COF, they form a well-defined and potentially porous network with specific properties.The resulting COF structure offers advantages such as tunable porosity, stability, and potential for selective adsorption of molecules due to its ordered and structured framework. This COF can find applications in areas such as gas storage, catalysis, or as a platform for controlled release or separation of molecules. | price> |
R-C-3181 | OP-3633 CAS:2102494-14-2 | OP-3633 is a potent and selective steroidal glucocorticoid receptor(GR)antagonist with an IC50 of 29 nM, with inhibition of GR transcriptional activity.OP-3633 exhibits low progesterone receptor(PR)agonism and androgen receptor(AR)antagonism. | price> |
R-R-4851 | TAPB-DHTP-COF | TAPB-DHTP-COF refers to a Covalent Organic Framework (COF) constructed using TAPB (1,3,5-tris(4-aminophenyl)benzene) and DHTP (2,6-dihydroxyterephthalaldehyde) as building blocks. This combination results in a structured material with specific properties derived from these components.1,3,5-tris(4-aminophenyl)benzene (TAPB) is a molecule with three amine groups attached to a benzene core, while 2,6-dihydroxyterephthalaldehyde (DHTP) contains two hydroxyl groups linked to a terephthalaldehyde backbone. When these components are linked through covalent bonds to form a COF, they create an ordered framework with potential porosity and specific chemical properties.The TAPB-DHTP-COF structure offers advantages such as tunable porosity, potential for molecular sieving, and tailored chemical reactivity due to its designed framework. These properties make it potentially useful in applications such as gas storage, catalysis, membrane technology, or sensing where controlled interactions with molecules are crucial. | price> |
R-C-3182 | PF 3716556 CAS:928774-43-0 | PF 3716556 is a potent and selective P-CAB(potassium-competitive acid blocker),with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay,respectively,inhibits gastric acid secretion,displays no activity at Na+,K+-ATPase. | price> |
R-R-4852 | COF-367-Cu | COF-367-Cu/Covalent Organic Framework-367-Cu refers to a specific type of Covalent Organic Framework (COF) that incorporates copper (Cu) atoms into its structure. COF-367 itself is a well-known COF characterized by its unique properties and applications.COF-367 is typically composed of organic building blocks that are linked together through strong covalent bonds, forming a porous and crystalline structure. The introduction of copper (Cu) atoms into this framework can enhance certain properties or introduce new functionalities due to the interaction of copper with the organic components.The incorporation of copper in COF-367-Cu can lead to improved catalytic properties, enhanced stability, or modified electronic properties compared to the non-metalated version of the COF. This can expand the potential applications of COF-367-Cu in areas such as catalysis, gas storage, sensing, or as a platform for controlled release of molecules. | price> |
R-C-3183 | Bufalin CAS:465-21-4 | Bufalin(BF)is a potent inhibitor of steroid receptor coactivator SRC-3,SRC-1 and Na+/K+-ATPase. Bufalin binds to the subunit α1,α2 and α3 of Na+/K+-ATPase with Kd of 42.5 nM, 45 nM and 40 nM, respectively. | price> |
R-R-4853 | Gemcitabine elaidate hydrochloride CAS No.2918768-08-6 | Gemcitabine elaidate (CP-4126) hydrochloride/CAS No.2918768-08-6 is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity. | price> |
R-C-3184 | PPQ-102 CAS:931706-15-9 | PPQ-102(CFTR Inhibitor IV)is a potent inhibitor of CFTR.PPQ-102 can completely inhibit CFTR chloride current with IC50 of ~90nM. | price> |
R-R-4854 | Rabacfosadine CAS No.859209-74-8 | Rabacfosadine (GS-9219)/CAS No.859209-74-8, a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells. | price> |
R-C-3185 | KM 11060 CAS:774549-97-2 | KM 11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation carried by 90% of cystic fibrosis patients.KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity. | price> |
R-R-4855 | 5-(Hydroxymethyl)cytidine CAS No.19235-17-7 | 5-(Hydroxymethyl)cytidine/CAS No.19235-17-7 is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc. | price> |
R-C-3186 | GLPG2451 CAS:2055015-61-5 | GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC50 of 11.1 nM. | price> |
R-R-4856 | Valopicitabine dihydrochloride CAS No.640725-71-9 | Valopicitabine (NM283) dihydrochloride/CAS No.640725-71-9 is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination. | price> |
R-C-3187 | Caldaret (MCC-135) CAS:133804-44-1 | Caldaret is an intracellular Ca2+ handling modulator that acts through reverse mode Na+/Ca2+ exchanger inhibition. | price> |
R-R-4857 | Adenosine-d2 CAS No.82741-17-1 | Adenosine-d2/CAS No.82741-17-1 is the deuterium labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physio. | price> |
R-C-3188 | TTA-Q6 CAS:910484-28-5 | TTA-Q6 is a selective T-type Ca2+ channel antagonist, which can be used in the research of neurological disease. | price> |
R-R-4858 | 3-O-Methylguanosine CAS No.10300-27-3 | 3-O-Methylguanosine/CAS No.10300-27-3 is a methylated nucleoside analogs and a RNA chain terminator. 3-O-methylguanosine can inhibit early virus-specific RNA synthesis. | price> |
R-C-3189 | GV-58 CAS:1402821-41-3 | GV-58 is a potent, selective N- and P/Q-type Ca2+ channels agonist with EC50 of 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel; 20-fold less potent CDK inhibitor activity. | price> |